Development of drugs to target interactions between leukocytes and endothelial cells and treatment algorithms for inflammatory bowel diseases

Gastroenterology

Volumn 147, Issue 5, 2014, Pages 981-989

  Danese, Silvio ^a   Panés, Julián ^b  

^a HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^b HOSPITAL CLÍNIC   (Spain)

Author keywords

Crohn's Disease; Drug Development; Immune Regulation; Ulcerative Colitis

Indexed keywords

ABRILUMAB; AGENTS USED IN INFLAMMATORY BOWEL DISEASE; AJM 300; ALPHA4 INTEGRIN; CELL ADHESION MOLECULE; CHEMOKINE RECEPTOR CCR9; ELDELUMAB; ETROLIZUMAB; GAMMA INTERFERON INDUCIBLE PROTEIN 10; NATALIZUMAB; PF 00547659; UNCLASSIFIED DRUG; VEDOLIZUMAB; VERCIRNON; ANTIINFLAMMATORY AGENT; GASTROINTESTINAL AGENT;

CELL INTERACTION; CROHN DISEASE; DISEASE ASSOCIATION; DRUG APPROVAL; DRUG DEVELOPMENT; DRUG EFFICACY; DRUG SAFETY; ENDOTHELIUM CELL; EVIDENCE BASED PRACTICE; FOOD AND DRUG ADMINISTRATION; HUMAN; INFLAMMATORY BOWEL DISEASE; LEUKOCYTE; META ANALYSIS (TOPIC); MULTICENTER STUDY (TOPIC); PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; ULCERATIVE COLITIS; ALGORITHM; ANIMAL; CELL COMMUNICATION; CLINICAL PROTOCOL; DRUG DESIGN; DRUG EFFECTS; IMMUNOLOGY; INFLAMMATORY BOWEL DISEASES; INTESTINE; METABOLISM; MOLECULARLY TARGETED THERAPY; SIGNAL TRANSDUCTION; VASCULARIZATION;

ALGORITHMS; ANIMALS; ANTI-INFLAMMATORY AGENTS; CELL COMMUNICATION; CLINICAL PROTOCOLS; DRUG DESIGN; ENDOTHELIAL CELLS; GASTROINTESTINAL AGENTS; HUMANS; INFLAMMATORY BOWEL DISEASES; INTESTINES; LEUKOCYTES; MOLECULAR TARGETED THERAPY; SIGNAL TRANSDUCTION;

EID: 84908296732     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2014.08.044     Document Type: Review

References (52)

1. D.C. Baumgart, and S.R. Carding Inflammatory bowel disease: cause and immunobiology Lancet 369 2007 1627 1640
2. M.A. Engel, and M.F. Neurath New pathophysiological insights and modern treatment of IBD J Gastroenterol 45 2010 571 583
3. V. Billioud, W.J. Sandborn, and L. Peyrin-Biroulet Loss of response and need for adalimumab dose intensification in Crohn's disease: a systematic review Am J Gastroenterol 106 2011 674 684
4. J.P. Gisbert, and J. Panes Loss of response and requirement of infliximab dose intensification in Crohn's disease: a review Am J Gastroenterol 104 2009 760 767
5. L. Peyrin-Biroulet, and M. Lemann Review article: remission rates achievable by current therapies for inflammatory bowel disease Aliment Pharmacol Ther 33 2011 870 879
6. K. Nakamura, K. Honda, and T. Mizutani Novel strategies for the treatment of inflammatory bowel disease: selective inhibition of cytokines and adhesion molecules World J Gastroenterol 12 2006 4628 4635
7. S. Danese New therapies for inflammatory bowel disease: from the bench to the bedside Gut 61 2012 918 932
8. L. Peyrin-Biroulet, P. Desreumaux, and W.J. Sandborn Crohn's disease: beyond antagonists of tumour necrosis factor Lancet 372 2008 67 81
9. S. Danese, S. Semeraro, and M. Marini Adhesion molecules in inflammatory bowel disease: therapeutic implications for gut inflammation Dig Liver Dis 37 2005 811 818
10. J. Panes, M. Perry, and D.N. Granger Leukocyte-endothelial cell adhesion: avenues for therapeutic intervention Br J Pharmacol 126 1999 537 550
11. M. Sans, J. Panes, and E. Ardite VCAM-1 and ICAM-1 mediate leukocyte-endothelial cell adhesion in rat experimental colitis Gastroenterology 116 1999 874 883
12. J. Panes, D.C. Anderson, and M. Miyasaka Role of leukocyte-endothelial cell adhesion in radiation-induced microvascular dysfunction in rats Gastroenterology 108 1995 1761 1769
13. D.G. Binion, G.A. West, and K. Ina Enhanced leukocyte binding by intestinal microvascular endothelial cells in inflammatory bowel disease Gastroenterology 112 1997 1895 1907
14. C.H. Polman, P.W. O'Connor, and E. Havrdova A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis N Engl J Med 354 2006 899 910
15. R.A. Rudick, W.H. Stuart, and P.A. Calabresi Natalizumab plus interferon beta-1a for relapsing multiple sclerosis N Engl J Med 354 2006 911 923
16. T.A. Yednock, C. Cannon, and L.C. Fritz Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin Nature 356 1992 63 66
17. W.J. Sandborn, J.F. Colombel, and R. Enns Natalizumab induction and maintenance therapy for Crohn's disease N Engl J Med 353 2005 1912 1925
18. S.R. Targan, B.G. Feagan, and R.N. Fedorak Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial Gastroenterology 132 2007 1672 1683
19. T. Lobaton, S. Vermeire, and G. Van Assche Review article: anti-adhesion therapies for inflammatory bowel disease Aliment Pharmacol Ther 39 2014 579 594
20. G. Bloomgren, S. Richman, and C. Hotermans Risk of natalizumab-associated progressive multifocal leukoencephalopathy N Engl J Med 366 2012 1870 1880
21. T.A. Yousry, E.O. Major, and C. Ryschkewitsch Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy N Engl J Med 354 2006 924 933
22. M. Jovani, and S. Danese Vedolizumab for the treatment of IBD: a selective therapeutic approach targeting pathogenic a4b7 cells Curr Drug Targets 14 2013 1433 1443
23. E. Fedyk, V. Csizmadia, and W. Shyu The gastrointestinal-selective biologic vedolizumab does not impair immune surveillance of the central nervous system in non-human primates Inflamm Bowel Dis 17 2011 S4 S5
24. B.G. Feagan, P. Rutgeerts, and B.E. Sands Vedolizumab as induction and maintenance therapy for ulcerative colitis N Engl J Med 369 2013 699 710
25. W.J. Sandborn, B.G. Feagan, and P. Rutgeerts Vedolizumab as induction and maintenance therapy for Crohn's disease N Engl J Med 369 2013 711 721
26. B.E. Sands, B.G. Feagan, and P. Rutgeerts Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed Gastroenterology 147 2014 618 627.e3
27. Sands B, Hanauer S, Danese S, et al. Reductions in corticosteroid use in patients with ulcerative colitis or Crohn's disease treated with vedolizumab. Presented at: 21st United European Gastroenterology Week; October 12-16, 2013; Berlin, Germany.
28. B.G. Feagan, G.R. Greenberg, and G. Wild Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin N Engl J Med 352 2005 2499 2507
29. B.G. Feagan, G.R. Greenberg, and G. Wild Treatment of active Crohn's disease with MLN0002, a humanized antibody to the alpha4beta7 integrin Clin Gastroenterol Hepatol 6 2008 1370 1377
30. P.J. Rutgeerts, R.N. Fedorak, and D.W. Hommes A randomised phase I study of etrolizumab (rhuMAb beta7) in moderate to severe ulcerative colitis Gut 62 2013 1122 1130
31. S. Vermeire Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial Lancet 26 2014 309 318
32. S. Vermeire, S. Ghosh, and J. Panes The mucosal addressin cell adhesion molecule antibody PF-00547,659 in ulcerative colitis: a randomised study Gut 60 2011 1068 1075
33. K.A. Papadakis, J. Prehn, and S.T. Moreno CCR9-positive lymphocytes and thymus-expressed chemokine distinguish small bowel from colonic Crohn's disease Gastroenterology 121 2001 246 254
34. S. Keshav, T. Vanasek, and Y. Niv A randomized controlled trial of the efficacy and safety of CCX282-B, an orally-administered blocker of chemokine receptor CCR9, for patients with Crohn's disease PLoS One 8 2013 e60094
35. L. Mayer, W.J. Sandborn, and Y. Stepanov Anti-IP-10 antibody (BMS-936557) for ulcerative colitis: a phase II randomised study Gut 63 2014 442 450
36. W. Sandborn, J.-F. Colombe, and S. Ghosh Phase IIB, randomized, placebo-controlled evaluation of the efficacy and safety of induction therapy with eldelumab (anti-IP-10 antibody; BMS-936557) in patients with active ulcerative colitis (abstr) Gastroenterology 146 suppl 2014 S-150
37. K.J. Baldwin, and J.P. Hogg Progressive multifocal leukoencephalopathy in patients with multiple sclerosis Curr Opin Neurol 26 2013 318 323
38. Biogen Idec Inc. Highlights of prescribing information: Tysabri 2013. http://www.tysabri.com/pdfs/I61061-13-PI.pdf.
39. Biogen Idec Inc. TYSABRI: Highlights of prescribing information 2013 [updated December 2013]. http://www.accessdata.fda.gov/drugsatfda-docs/label/2013/125104s840s847s889lbl.pdf.
40. D'Haens G, Vermeire S, Cataldi F, et al, eds. Anti-MAdCAM monoclonal antibody PF-00547659 does not affect immune surveillance in the central nervous system of anti-TNF and immunosuppressant experienced Crohn's disease patients who are anti-TNF inadequate responders: results from the TOSCA study. Presented at: 9th Congress of the European Crohn's and Colitis Organisation; February 20-22, 2014; Copenhagen, Denmark.
41. Clifford DB, McAuliffe M, Stephens K, et al. Risk Assessment and minimization for progressive multifocal leukoencephalopathy (PML RAMP): a program to assess for potential early signs and symptoms of PML during clinical development of vedolizumab. Presented at: 78th Annual Scientific Meeting of the American College of Gastroenterology; October 11-16, 2013; San Diego, CA.
42. Colombe J-F, Sands B, Hanauer S, et al. Long-term safety of vedolizumab for the treatment of ulcerative colitis or Crohn's disease. Presented at: 78th Annual Scientific Meeting of the American College of Gastroenterology; October 11-16, 2013; San Diego, CA.
43. S. Danese, G. Fiorino, and L. Peyrin-Biroulet Biological agents for moderately to severely active ulcerative colitis: a systematic review and network meta-analysis Ann Intern Med 160 2014 704 711
44. P. Rutgeerts, W.J. Sandborn, and B.G. Feagan Infliximab for induction and maintenance therapy for ulcerative colitis N Engl J Med 353 2005 2462 2476
45. A. Oussalah, L. Evesque, and D. Laharie A multicenter experience with infliximab for ulcerative colitis: outcomes and predictors of response, optimization, colectomy, and hospitalization Am J Gastroenterol 105 2010 2617 2625
46. J.F. Colombel, W.J. Sandborn, and P. Rutgeerts Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial Gastroenterology 132 2007 52 65
47. S.B. Hanauer, W.J. Sandborn, and P. Rutgeerts Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial Gastroenterology 130 2006 323 333 quiz 591
48. S.B. Hanauer, B.G. Feagan, and G.R. Lichtenstein Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial Lancet 359 2002 1541 1549
49. B.E. Sands, F.H. Anderson, and C.N. Bernstein Infliximab maintenance therapy for fistulizing Crohn's disease N Engl J Med 350 2004 876 885
50. A.C. Ford, W.J. Sandborn, and K.J. Khan Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis Am J Gastroenterol 106 2011 644 659 quiz 660
51. P. Rutgeerts, G. Van Assche, and W.J. Sandborn Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial Gastroenterology 142 2012 1102 1111.e2
52. S. Schreiber, J.F. Colombel, and R. Bloomfield Increased response and remission rates in short-duration Crohn's disease with subcutaneous certolizumab pegol: an analysis of PRECiSE 2 randomized maintenance trial data Am J Gastroenterol 105 2010 1574 1582